FOLLOWUS
In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells
In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells
- 中国结合医学杂志（英文版） 2011年17卷第7期 页码：517-524
- Affiliations：
Department of Oncology, Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai,China
- Author bio：
- Funds：Supported by the National Natural Science Foundation of China (No. 30672683)
DOI：10.1007/s11655-011-0785-0
中图分类号：纸质出版日期：2011，
网络出版日期：2011-7-3，
Scan for full text
Li, J., Fan, Zz., Sun, J. et al. , In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells., Chin. J. Integr. Med. 17, 517–524 (2011). https://doi.org/10.1007/s11655-011-0785-0
Jing Li, Zhong-ze Fan, Jue Sun, et al. In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells[J]. Chinese Journal of Integrative Medicine, 2011,17(7):517-524.
Li, J., Fan, Zz., Sun, J. et al. , In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells., Chin. J. Integr. Med. 17, 517–524 (2011). https://doi.org/10.1007/s11655-011-0785-0 DOI：
Jing Li, Zhong-ze Fan, Jue Sun, et al. In Vitro antimetastatic effect of Changweiqing (肠胃清) through antiinvasion of hypoxic colorectal carcinoma LoVo cells[J]. Chinese Journal of Integrative Medicine, 2011,17(7):517-524. DOI： 10.1007/s11655-011-0785-0.
摘要
To investigate the in vitro effects and the primary mechanisms of Changweiqing (肠胃清
CWQ) on antimetastasis and antiinvasion of hypoxic colon carcinoma cells. In addition
to provide experimental evidence for the Chinese medicinal theory of “strengthening the body’s resistance to eliminate pathogenic factors” in the treatment of colorectal cancer
including its invasion and metastasis. First
CWQ sera were prepared with serum-pharmacology methods. Then
the modified hypoxic chamber was designed and flushed with 5% CO2 and 95% N2 at 37 °C to induce a hypoxic environment. The effect of CWQ serum on the viability of LoVo cells was tested with MTT cytotoxicity assay. The wound model and chamber model were established to estimate the effects of CWQ serum on migration and invasion of LoVo cells. The model for cell adhesion was established to evaluate the effect of CWQ serum on LoVo cells’ adhesion. The gelatin zymography model was performed to determine the effects of CWQ serum on the activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The effects of CWQ serum on the hypoxia-inducible factor 1 α (HIF-1α) nuclear translocation and the mRNA level of vascular endothelial growth factor (VEGF) in LoVo cells were determined by Western blot and reverse transcription-polymerase chain reaction (RT-PCR) analyses
respectively. CWQ inhibited LoVo cells’ migration based on wound healing assay. The inhibitive effect could reach about 68.00% under hypoxic culture and about 29.87% under normoxic culture when cells were treated with 10% CWQ serum for 24 h. The results from both cell invasion and adhesion assays showed that CWQ serum could dose-dependently repress the invasion of LoVo cells and inhibit cells from adhering to extra cellular matrix (ECM). Under the hypoxic culture condition
RT-PCR analysis showed that 10% CWQ serum had down-regulated the expression of VEGF by 45.87%
and the result of Western blot analysis provided further evidence. The HIF-1α amount in the nucleus of the LoVo cells was also diminished in a dose-dependent manner
as shown by the Western blot. Gel zymogram assay revealed that CWQ serum could suppress the activities of MMP-2 and MMP-9. CWQ could effectively inhibit tumor metastasis in vitro The antimetastatic effects of CWQ were associated with the inhibition of cell motility
which was evidenced by inhibition of cell invasion and adhesion. The molecular mechanisms of the inhibition of tumor invasion by CWQ were due to the reduced expression of both HIF-1α and VEGF and the suppression of MMP-2 and MMP-9 expression.
Abstract
To investigate the in vitro effects and the primary mechanisms of Changweiqing (肠胃清
CWQ) on antimetastasis and antiinvasion of hypoxic colon carcinoma cells. In addition
to provide experimental evidence for the Chinese medicinal theory of “strengthening the body’s resistance to eliminate pathogenic factors” in the treatment of colorectal cancer
including its invasion and metastasis. First
CWQ sera were prepared with serum-pharmacology methods. Then
the modified hypoxic chamber was designed and flushed with 5% CO2 and 95% N2 at 37 °C to induce a hypoxic environment. The effect of CWQ serum on the viability of LoVo cells was tested with MTT cytotoxicity assay. The wound model and chamber model were established to estimate the effects of CWQ serum on migration and invasion of LoVo cells. The model for cell adhesion was established to evaluate the effect of CWQ serum on LoVo cells’ adhesion. The gelatin zymography model was performed to determine the effects of CWQ serum on the activities of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9). The effects of CWQ serum on the hypoxia-inducible factor 1 α (HIF-1α) nuclear translocation and the mRNA level of vascular endothelial growth factor (VEGF) in LoVo cells were determined by Western blot and reverse transcription-polymerase chain reaction (RT-PCR) analyses
respectively. CWQ inhibited LoVo cells’ migration based on wound healing assay. The inhibitive effect could reach about 68.00% under hypoxic culture and about 29.87% under normoxic culture when cells were treated with 10% CWQ serum for 24 h. The results from both cell invasion and adhesion assays showed that CWQ serum could dose-dependently repress the invasion of LoVo cells and inhibit cells from adhering to extra cellular matrix (ECM). Under the hypoxic culture condition
RT-PCR analysis showed that 10% CWQ serum had down-regulated the expression of VEGF by 45.87%
and the result of Western blot analysis provided further evidence. The HIF-1α amount in the nucleus of the LoVo cells was also diminished in a dose-dependent manner
as shown by the Western blot. Gel zymogram assay revealed that CWQ serum could suppress the activities of MMP-2 and MMP-9. CWQ could effectively inhibit tumor metastasis in vitro The antimetastatic effects of CWQ were associated with the inhibition of cell motility
which was evidenced by inhibition of cell invasion and adhesion. The molecular mechanisms of the inhibition of tumor invasion by CWQ were due to the reduced expression of both HIF-1α and VEGF and the suppression of MMP-2 and MMP-9 expression.
关键词
Changweiqingmetastasishypoxia-inducible factor 1 αmatrix metalloproteinasevascular endothelial growth factor
Keywords
Changweiqingmetastasishypoxia-inducible factor 1 αmatrix metalloproteinasevascular endothelial growth factor
references
Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23–47.
Kato R, Ishikawa T, Kamiya S, Oguma F, Ueki M, Goto S, et al. A new type of antimetastatic peptide derived from fibronectin. Clin Cancer Res 2002;8:2455–2462.
Cora NS. Metastatic bladder cancer: role of chemotherapy and new agents. EAU Update Ser 2003;1:108–117.
Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856–1862.
Levine E, Raghaven D. MVAC for bladder cancer-time to move forward again. J Clin Oncol 1993;11:387–389.
Woessner Jr JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145–2154.
Matrisian LM. The matrix-degrading metalloproteinases. Bioessays 1992;14:455–463.
Stetler-Stevenson WG. Type IV collagenases in tumor invasion and metastasis. Cancer Metast Rev 1990;9:289–303.
Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.
Gale NW, Yancopoulos GD. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999;13:1055–1066.
Yancopoulos GD, Klagsbrun M, Folkman J. Vasculogenesis, angiogenesis, and growth factors: ephrins enter the fray at the border. Cell 1998;93:661–664.
Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000;36:1649–1660.
Mohamed KM, Le A, Duong H, Wu Y, Zhang Q, Messadi DV. Correlation between VEGF and HIF-1α expression in human oral squamous cell carcinoma. Exp Mol Pathol 2004;76:143–152.
Levy AP, Levy NS, Goldberg MA. Post-transcriptional regulation of vascular endothelial factor by hypoxia. J Biol Chem 1996;271:2746–2753.
Schweiki D, Itan A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxiainitiated angiogenesis. Nature 1992;359:843–845.
Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104–8109.
Lin C, McGough R, Aswad B, Block JA, Terek R. Hypoxia induces HIF-1α and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 2004;22:1175–1181.
Xu JH, Fan ZZ, Sun J, Zhu MH, Fei RY, Han JH, et al. Effects of “Chang Wei Qing” in treating advanced gastrointestinal cancer and its effects on periphereal blood MDR1 mRNA. Shanghai J Tradit Chin Med (Chin) 2007;41:40–42.
Malhotra R, Tyson DGW, Sone H, Aoki K, Kumagai AK, Brosius FC. Glucose uptake and adenoviral mediated GLUT1 infection decrease hypoxia-induced HIF-1α levels in cardiac myocytes. J Mol Cell Cardiol 2002;34:1063–1073.
Liu JW, Kayasuga A, Nagao N, Masatsuji-Kato E, Tuzuki T, Miwa N. Repressions of actin assembly and RhoA localization are involved in inhibition of tumor cell motility by lipophilic ascorbyl phosphate. Int J Oncol 2003;23:1561–1567.
Liu JW, Norio N, Kageyama K, Miwa N. Anti-metastatic and anti-invasive ability of phospho-ascorbyl palmitate through intracellular ascorbate enrichmet and the resultant antioxidant action. Oncol Res 1999;11:479–487.
Liu JW, Norio N, Kageyama K, Miwa N. Anti-metastatic effect of an autooxidation-resistant and lipophilic ascorbic acid derivative through inhibition of tumor invasion. Anticancer Res 2000;20:113–118.
Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci 2001;21:92–97.
Sugiyama T, Sadzuka Y. Combination of theanine with doxorubicin inhibits hepatic metastasis of M5076 ovarian sarcoma. Clin Cancer Res 1999;5:413–416.
Liotta LA. Tumor invasion and metastases-role of the extracellular matrix. Cancer Res 1986;46:1–7.
Glinsky GV, Glinsky VV. Apoptosis and metastasis: a superior resistance of metastatic cancer cells to programmed cell death. Cancer Lett 1996;101:43–51.
Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003;83:337–376.
Yamada KM, Kennedy DW, Yamada SS, Gralnick H, Chen WT, Akiyama SK. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. Cancer Res 1990;50:4485–4496.
Elkin M, Reich R, Nagler A, Aingorn E, Pines M, de-Groot N, et al. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by Halofuginone. Clin Cancer Res 1999;5:1982–1988.
Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer I 2001;93:178–193.
Mönig SP, Baldus SE, Hennecken JK, Spiecker DB, Grass G, Schneider PM, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology 2001;39:597–602.
Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, et al. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996;74:413–417.
Kabashima A, Maehara Y, Kakeji Y, Baba H, Koga T, Sugimachi K. Clinicopathological features and overexpression of matrix metalloproteinases in intramucosal gastric carcinoma with lymph node metastasis. Clin Cancer Res 2000;6:3581–3584.
Sanceau J, Truchet S, Bauvois B. Matrix metalloproteinase-9 silencine by RNA interference triggers the migration-adhesive switch in Ewing sarcoma cells. J Biochem 2003;278:1–25.
Sun S, Schiller JH. Angiogenesis inhibitors in the treatment of lung cancer. Crit Rev Oncol Hemat 2007;62:93–104.
Salven P, Heikkila P, Joensuu H. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Brit J Cancer 1997;76:930–934.
Wong MP, Cheung N, Yuen ST, Leung SY, Chung LP. Vascular endothelial growth factor is upregulated in early premalignant stage of colorectal tumor progression. Int J Cancer 1999;81:845–850.
Semela D, Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol 2004;41:864–880.
Jaffar M, Williams KJ, Stratford IJ. Bioreductive and gene therapy approaches to hypoxic diseases. Adv Drug Deliver Rev 2001;53:217–228.
Rofstad EK, Mathiesen B, Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res 2004;64:13–18.
Giatromanolaki A, Koukourakis MI, Sowter HM, Sivridis E, Gibson S, Gatter KC, et al. BNIP3 expression is linked with hypoxia-regulated protein expression and with poor prognosis in non-small cell lung cancer. Clin Cancer Res 2004;10:5566–5571.
Saarikoski ST, Rivera SP, Hankinson O. Mitogen-inducible gene 6 (MIG-6), adipophilin and tuftelin are inducible by hypoxia. FEBS. Lett 2002;530:186–190.
Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995;92:5510–5514.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271–275.
Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272:22642–22647.
Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004;5:437–448.
0
浏览量
927
Downloads
6
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
